Curative intent therapy for DLBCL in the elderly

References

• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by Sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105(11):1684–1692. doi:10.1038/bjc.2011.450
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M. SEER cancer statistic review, 1975–2017. National Cancer Institute; April 2020 (based on November 2019 SEER data submission). Accessed 1 December 2020. Available from: https://seer.cancer.gov/crs/1975_2017
   Google Scholar
• Soverini G, Tucci A. Clinical geriatric assessment in older patients with lymphoma: a narrative review. Ann Lymphoma. 2022;6:11–11. doi:10.21037/aol-22-6
   Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–2603. doi:10.1200/JCO.2013.54.8347
   PubMed Web of Science ®Google Scholar
• Buske C, Hutchings M, Ladetto M, et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 2018;29(3):544–562. doi:10.1093/annonc/mdx413
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the fondazione italiana linfomi. J Clin Oncol. 2021;39(11):1214–1222. doi:10.1200/JCO.20.02465
   PubMed Web of Science ®Google Scholar
• Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019;134(4):374–382. doi:10.1182/blood.2019000758
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised european consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Lee S, Fujita K, Morishita T, et al. Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol. 2021;192(1):100–109. doi:10.1111/bjh.16743
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi:10.1056/NEJMra2027612
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947. doi:10.1056/NEJMoa012914
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Salles G, Falandry C. The biology of aging and lymphoma: a complex interplay. Curr Oncol Rep. 2015;17(7):32. doi:10.1007/s11912-015-0457-x
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d‘Etude des lymphomes de l‘Adulte. J Clin Oncol. 2005;23(18):4117–4126. doi:10.1200/JCO.2005.09.131
   PubMed Web of Science ®Google Scholar
• Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the lymphoma italian foundation (FIL). Leuk Lymphoma. 2015;56(4):921–926. doi:10.3109/10428194.2014.953142
   PubMed Web of Science ®Google Scholar
• Kühnl A, Cunningham D, Counsell N, et al. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017;28(7):1540–1546. doi:10.1093/annonc/mdx128
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116. doi:10.1016/S1470-2045(08)70002-0
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328. doi:10.1200/JCO.20.01366
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-Germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662. doi:10.1016/S1470-2045(18)30935-5
   PubMed Web of Science ®Google Scholar
• Davies AJ, Barrans S, Stanton L, et al. Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-Up. J Clin Oncol. 2023;41(15):2718–2723. doi:10.1200/JCO.23.00033
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD anderson cancer center clinical experience. Br J Haematol. 2014;166(6):891–901. doi:10.1111/bjh.12982
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361. doi:10.1182/blood-2014-05-578963
   PubMed Web of Science ®Google Scholar
• Dodero A, Guidetti A, Marino F, et al. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica. 2022;107(5):1153–1162. doi:10.3324/haematol.2021.278638
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799. doi:10.1200/JCO.18.01994
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi:10.1056/NEJMoa2115304
   PubMed Web of Science ®Google Scholar
• Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016;7(4):249–257. doi:10.1016/j.jgo.2015.12.002
   PubMed Web of Science ®Google Scholar
• Eyre TA, Martinez-Calle N, Hildyard C, et al. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med. 2019;285(6):681–692. doi:10.1111/joim.12889
   PubMed Web of Science ®Google Scholar
• Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a danish population-based cohort study. Eur J Cancer. 2018;99:86–96. doi:10.1016/j.ejca.2018.05.006
   PubMed Web of Science ®Google Scholar
• Tucci A, Merli F, Fabbri A, et al. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the elderly project of the fondazione italiana linfomi (FIL). Haematologica. 2023;108(4):1083–1091. doi:10.3324/haematol.2022.281407
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468. doi:10.1016/S1470-2045(11)70069-9
   PubMed Web of Science ®Google Scholar
• Merli F, Cavallo F, Salvi F, et al. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by fondazione italiana linfomi. J Geriatr Oncol. 2020;11(1):37–40. doi:10.1016/j.jgo.2019.06.020
   PubMed Web of Science ®Google Scholar
• Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom national cancer research institute trial. J Clin Oncol. 2014;32(4):282–287. doi:10.1200/JCO.2013.49.7586
   PubMed Web of Science ®Google Scholar
• Shen QD, Zhu HY, Wang L, et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018;5(6):e261–e269. doi:10.1016/S2352-3026(18)30054-1
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian cancer drug therapy working group [arbeitsgemeinschaft medikamentöse tumortherapie AGMT] (NHL-14). Eur J Cancer. 2016;58:112–121. doi:10.1016/j.ejca.2016.02.004
   PubMed Web of Science ®Google Scholar
• Luminari S, Viel E, Ferreri AJM, et al. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the fondazione italiana linfomi. Hematol Oncol. 2018;36(1):68–75. doi:10.1002/hon.2425
   PubMed Web of Science ®Google Scholar
• Rigacci L, Annibali O, Kovalchuk S, et al. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. Hematol Oncol. 2020;38(4):478–486. doi:10.1002/hon.2764
   PubMed Web of Science ®Google Scholar
• Arcari A, Rigacci L, Tucci A, et al. A fondazione italiana linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. Blood Adv. 2023;7(15):4160–4169. doi:10.1182/bloodadvances.2023009839
   PubMed Web of Science ®Google Scholar
• Cencini E, Tucci A, Puccini B, et al. The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the fondazione italiana linfomi. Hematol Oncol. 2023;41(1):78–87. doi:10.1002/hon.3081
   PubMed Web of Science ®Google Scholar
• Lakshmaiah KC, Asati V, Babu K G, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018;100(6):644–648. doi:10.1111/ejh.13068
   PubMed Web of Science ®Google Scholar
• Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46–e55. doi:10.1016/S2352-3026(16)30171-5
   PubMed Web of Science ®Google Scholar
• Lin RJ, Owens CN, Drill E, et al. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2022;107(5):1144–1152. doi:10.3324/haematol.2021.278719
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2009;20(4):162–165. doi:10.1093/annonc/mdp162
   PubMedGoogle Scholar
• Herrstedt J, Lindberg S, Petersen PC. Prevention of chemotherapy-Induced nausea and vomiting in the older patient: optimizing outcomes. Drugs Aging. 2022;39(1):1–21. doi:10.1007/s40266-021-00909-8
   PubMed Web of Science ®Google Scholar
• Storti S, Spina M, Pesce EA, et al. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the fondazione italiana linfomi. Haematologica. 2018;103(8):1345–1350. doi:10.3324/haematol.2017.186569
   PubMed Web of Science ®Google Scholar
• Lugtenburg PJ, Mutsaers PGNJ. How I treat older patients with DLBCL in the frontline setting. Blood. 2023;141(21):2566–2575. doi:10.1182/blood.2020008239
   PubMed Web of Science ®Google Scholar
• Jardin F, Tilly H. Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm? Lancet Healthy Longev. 2022;3(7):e453–e454. doi:10.1016/S2666-7568(22)00150-7
   PubMedGoogle Scholar
• Gini G, Tani M, Tucci A, et al. Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi phase 2 study. Blood. 2023;142(17):1438–1447. doi:10.1182/blood.2022019173
   PubMed Web of Science ®Google Scholar
• Xu PP, Shi ZY, Qian Y, et al. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. Lancet Healthy Longev. 2022;3(7):e481–e490. doi:10.1016/S2666-7568(22)00123-4
   PubMedGoogle Scholar
• Olszewski AJ, Avigdor A, Babu S, et al. Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 2020;136:43–45. doi:10.1182/blood-2020-136255
   Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi:10.1016/S1470-2045(20)30225-4
   PubMed Web of Science ®Google Scholar
• Tucci A, Musuraca G, Cavallo F, et al. A simplified geriatric assessment (sGA) can identify older patients with relapse/refractory (R/R) aggressive lymphoma suitable for autologous stem cell transplantation (ASCT): final results of recanz multicentre prospective phase 2 study by the fondazione italiana linfomi (FIL). Blood. 2021;138(1):2496–2496. doi:10.1182/blood-2021-149649
   Google Scholar
• Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–2109. doi:10.1182/blood.2019004162
   PubMed Web of Science ®Google Scholar
• Ram R, Grisariu S, Shargian-Alon L, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022;107(5):1111–1118. doi:10.3324/haematol.2021.278288
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Locke FL, Ma L, et al. Real-World evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022;28(9):581.e1–581.e8. doi:10.1016/j.jtct.2022.05.026
   PubMedGoogle Scholar
• Lin RJ, Kim SJ, Brown S, et al. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma. Blood Adv. 2023;7(14):3501–3505. doi:10.1182/bloodadvances.2023010003
   PubMed Web of Science ®Google Scholar
• Chihara D, Liao L, Tkacz J, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023;142(12):1047–1055. doi:10.1182/blood.2023020197
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/JCO.19.00172
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-Engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–2247. doi:10.1200/JCO.22.01725
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi:10.1016/S1470-2045(21)00139-X
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai WZ, Alderuccio JP, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 2023. doi:10.3324/haematol.2023.283459
   PubMed Web of Science ®Google Scholar